Prestige Consumer Healthcare Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Prestige Consumer Healthcare Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	882	1,041	976	963	943	1,087	1,128	1,125	1,138	1,089
Cost of revenue	382	465	420	411	396	466	502	501	503	493
Gross profit	500	577	556	552	547	621	625	624	634	596
Selling and marketing	128	147	143	147	141	157	145	153	156	149
General and administrative	89.1	85.4	89.8	89.1	83.1	107	107	106	108	116
Operating expenses	295	361	488	261	250	291	648	282	298	286
Operating income	206	215	67.5	291	297	330	-22.4	342	337	309
Interest expense	93.5	106	105	96.2	82.3	64.3	4.4	5.2	1.8
Interest income	0.2	0.39	0.22	0.34
Other non-operating income	-0.03	0.39	-0.48	-1.63	1.37	-1.05	-2.34	0.76	-4.95	-9.57
Pre-tax income	111	107	-38.1	191	204	262	-93.9	276	284	257
Income tax	41.5	-232	-2.26	48.9	39.4	57.1	-11.6	66.7	69.6	67.2
Net income	69.4	340	-35.8	142	165	205	-82.3	209	215	190
EBITDA	231	249	99.3	320	328	362	10.2	373	367	341
EPS, basic	1.31	6.40	-0.69	2.81	3.28	4.09	-1.65	4.21	4.32	3.93
EPS, diluted	1.30	6.34	-0.69	2.78	3.25	4.04	-1.65	4.17	4.29	3.91
Shares, basic (weighted)	53	53.1	52.1	50.7	50.2	50.3	49.9	49.8	49.7	48.5
Shares, diluted (weighted)	53.4	53.5	52.1	51.1	50.6	50.8	49.9	50.2	50.1	48.7

Balance sheet

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Cash and equivalents	41.9	32.5	27.5	94.8	32.3	27.2	58.5	46.5	97.9	63.9
Receivables	137	141	149	151	115	139	167	177	194	192
Inventory	116	119	120	116	115	120	162	139	148	159
Other current assets	40.2	11.5	4.74	4.35	7.9	6.41	4.12	13.1	8.44	16.6
Total current assets	334	303	301	366	270	293	392	375	448	431
Property, plant and equipment	50.6	52.6	51.2	56	70.1	71.3	70.4	76.5	74.5	122
Lease right-of-use assets			0	28.9	23.7	20.4	14.9	11.3	28.2	27.8
Goodwill	615	620	579	575	578	579	528	528	527	581
Intangible assets	2,904	2,781	2,507	2,479	2,476	2,697	2,342	2,321	2,295	2,300
Other non-current assets	7.45	3.57	3.13	2.96	2.86	3.27	3.01	5.73	3.27	10.9
Total assets	3,911	3,761	3,441	3,514	3,429	3,671	3,354	3,318	3,402	3,494
Accounts payable	70.2	61.4	56.6	62.4	46	55.8	62.7	39	18.9	22.8
Accrued liabilities	15.5	10.6	11	13.4	14.1	19.6	14.3	12.2	14.2	12.1
Short-term debt					0					0
Total current liabilities	162	123	127	150	122	143	161	117	107	121
Long-term debt	2,194	1,993	1,799	1,730	1,480	1,477	1,346	1,135		994
Lease liabilities			0	24.9	19.7	16.1	9.88	7.53	22.7	21
Other non-current liabilities	18	23.3	20.1	25.4	8.61	7.48	8.17	9.19	5.39	5.58
Total liabilities	3,089	2,582	2,345	2,343	2,071	2,093	1,907	1,663	1,567	1,607
Total debt	2,194	1,993	1,799	1,730	1,480	1,477	1,346	1,126	992	994
Paid-in capital	458	469	479	488	500	516	535	567	593	609
Retained earnings	397	736	702	844	1,009	1,214	1,132	1,341	1,556	1,746
Treasury stock	-6.59	-7.67	-59.9	-118	-131	-134	-189	-220	-277	-439
Other comprehensive income	-26.4	-19.3	-25.7	-44.2	-19.8	-19	-31.6	-34.5	-37.7	-28.4
Shareholders' equity	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655	1,835	1,888
Total equity	823	1,179	1,096	1,171	1,358	1,578	1,447	1,655	1,835	1,888
Total liabilities and equity	3,911	3,761	3,441	3,514	3,429	3,671	3,354	3,318	3,402	3,494

Cash flow statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Net income	69.4	340	-35.8	142	165	205	-82.3	209	215	190
Depreciation and amortization	25.8	33.4	31.8	29	30.2	32.1	32.6	30.7	30.2	31.3
Stock-based compensation	8.15	8.91	7.44	7.64	8.54	9.04	12.4	14	11.2	10.8
Deferred income tax	-5.78	-269	-40.6	13.9	18.6	9.98	-60.8	23.1	14.4	22.7
Change in receivables	-18.9	-5.04	-2.98	-2.85	36.9	-24.7	-24.9	-6.32	-16.3	-3.69
Change in inventory	-10.3	-2.48	-10.5	2.93	2.97	0.66	-42.2	24.4	-9.31	-1.6
Change in payables	21.4	-10	-3.99	6.21	-17.3	9.15	7.26	-25	-19.4	-0.15
Cash from operations	149	210	189	217	236	260	230	249	252	258
Capital expenditures	-2.98	-12.5	-10.5	-14.6	-22.2	-9.64	-7.78	-9.55	-8.22	-11.2
Acquisitions	0	0		-2.76	0	-247	0	-10.6	-8.25	-124
Cash from investing	-695	-11.6	55.4	-16.6	-22.2	-257	-11.6	-20.1	-17.5	-137
Debt issued	0	250	0	400	600	0	0
Debt repaid	0	0	0	-400	-600	0	0
Stock issued	4.03	1.62	2.93	1.32	2.85	7.04	7.37	18.1	14.8	4.29
Share buybacks	0	0	-50	-56.7	-11.9	0	-50	-25	-51.5	-156
Cash from financing	561	-209	-249	-131	-279	-7.57	-186	-241	-182	-156
Exchange rate effect	-0.41	1.1	-0.41	-1.89	3.6	-0.96	-0.98	0.18	-0.57	1.26
Net change in cash	14.6	-9.31	-5.02	67.2	-62.5	-5.12	31.3	-12	51.4	-34
Free cash flow	146	198	179	203	213	250	222	239	243	246
Interest paid	85.2	98.6	98.2	92.2	80.3	61.4	54.2	63.2	47.8	43.8
Income taxes paid	48	24.4	32.8	30.6	34.4	46.6	40.7	59.6	52.1	45.9

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $46.61 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	53.5%	Gross profit / revenue.
Operating margin	26.3%	Operating income / revenue.
EBITDA margin	29.2%	EBITDA (operating income + depreciation and amortization) / revenue.
Net margin	15.6%	Net income / revenue.
FCF margin	21.3%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	22.6%	Cash from operations / revenue.
Return on equity (ROE)	9.0%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	3.8%	Net income / average total assets.
Return on invested capital (ROIC)	6.0%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue	1.0%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	1.3%	Capital expenditures / revenue.
D&A / revenue	2.9%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-4.3%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-1.2%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	2.9%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-6.1%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	-1.6%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	1.7%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	-8.1%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 5y	0.8%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	-7.2%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	221.9%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	0.8%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	-11.3%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 5y	2.9%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y	-8.9%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 5y	3.8%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	2.4%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	3.9%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	1.8%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	1.3%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	3.6%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	2.9%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	2.9%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	9.3%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	6.8%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	2.7%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	1.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	0.4%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-2.7%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-0.8%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	-0.8%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	3.23x	Current assets / current liabilities.
Quick ratio	1.80x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.58x	(Cash + short-term investments) / current liabilities.
Debt / equity	1.05x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	44.2%	Total debt / total assets.
Liabilities / assets	58.0%	Total liabilities / total assets.
Net debt	$1.93B	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	5.98x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Working capital	$343.0M	Current assets - current liabilities.
Goodwill and intangibles / assets	85.2%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$1.98B	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.24x	Revenue / average total assets.
Fixed asset turnover	9.43x	Revenue / average property, plant and equipment.
Inventory turnover	2.70x	Cost of revenue / average inventory.
Days inventory	135 days	365 x average inventory / cost of revenue.
Receivables turnover	5.90x	Revenue / average receivables.
Days sales outstanding	62 days	365 x average receivables / revenue.
Days payables	26 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	171 days	Days inventory + days sales outstanding - days payables.
FCF conversion	136.8%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	5.6%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$3.61	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$23.21	Revenue / diluted weighted shares.
FCF per share	$4.94	Free cash flow / diluted weighted shares.
Operating cash flow per share	$5.24	Cash from operations / diluted weighted shares.
Book value per share	$40.26	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$41.54	Tangible book value / shares outstanding.
Cash per share	$1.87	(Cash + short-term investments) / shares outstanding.
Buybacks / FCF	51.6%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$2.21B	Share price x shares outstanding.
Enterprise value	$4.14B	Market cap + total debt - cash - short-term investments.
P/E	12.8x	Market cap / net income. Only when net income is positive.
P/S	2.00x	Market cap / revenue.
P/B	1.15x	Market cap / shareholders' equity. Only when equity is positive.
P/FCF	9.38x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	8.85x	Market cap / cash from operations, when positive.
EV/Sales	3.74x	Enterprise value / revenue.
EV/EBIT	14.3x	Enterprise value / operating income, when both are positive.
EV/EBITDA	12.8x	Enterprise value / EBITDA, when both are positive.
EV/FCF	17.6x	Enterprise value / free cash flow, when both are positive.
FCF yield	10.7%	Free cash flow / market cap.
Earnings yield	7.8%	Net income / market cap (the inverse of P/E).
Shareholder yield	5.5%	(Dividends paid + share buybacks) / market cap.

What was Prestige Consumer Healthcare Inc.'s revenue in fiscal 2026?

Prestige Consumer Healthcare Inc. reported revenue of $1.09B for fiscal 2026, 4.3% lower than the year before.

Was Prestige Consumer Healthcare Inc. profitable in fiscal 2026?

Yes. Net income was $190.3M, a net margin of 17.5%.

How much free cash flow did Prestige Consumer Healthcare Inc. generate in fiscal 2026?

Cash from operations of $257.6M minus capital expenditures of $11.2M left free cash flow of $246.4M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Prestige Consumer Healthcare Inc.